Personalized support that can help you start, stay, and save on treatment
Once you’ve been prescribed KISQALI, you or your loved one can sign up for Novartis Patient Support. It’s a comprehensive program with a dedicated team in your corner.
Once you’ve been prescribed KISQALI, you or your loved one can sign up for Novartis Patient Support. It’s a comprehensive program with a dedicated team in your corner.
You’ll have a dedicated team member with Novartis Patient Support. They’ll reach out from the start and get to know you. When you have questions, you can talk to them directly.
Ready to sign up?
Count on personalized assistance at every step. You’ll get help with:
Once your health care provider has filed the paperwork with your insurance, Novartis Patient Support can help with the rest.
Cost shouldn’t be a barrier between you and the treatment you need. Your support will be based on your unique financial situation. That will include things like your prescription and insurance. Novartis Patient Support offers options to help you afford your treatment.
Pay as little as $0* with your Co-Pay Plus offer
Once prescribed KISQALI and/or FEMARA, you can:
If your insurance coverage is denied or delayed, the Bridge Program can cover your costs during this period. You may get up to 12 months of KISQALI or the KISQALI FEMARA Co-Pack for free.† This gives Novartis Patient Support time to work with your provider to process your insurance.
Your Free Trial Offer for KISQALI is good for 1 treatment cycle of KISQALI FEMARA (2.5 mg tablets) Co-Pack or KISQALI and/or FEMARA (including generic letrozole) at no cost to you. This offer is available to all with a valid prescription—regardless of insurance. For one-time use only.
Get your first treatment cycle of any one of the following at no cost
KISQALI
FEMARA
Letrozole
KISQALI + FEMARA
KISQALI + letrozole
KISQALI FEMARA Co-Pack
If you’re experiencing financial hardship and/or have no third-party insurance coverage, we can help. Charitable organizations like Novartis Patient Assistance Foundation (NPAF) may help provide access to medications.
To be eligible for NPAF, you must:
Be a United States resident
Meet certain income requirements
Have limited or no prescription coverage
Visit PAP.novartis.com ↗ for a complete list of medications and income requirements. Get answers to your questions at 1-800-277-2254.
Getting you the medication you need is our number one priority. Novartis Patient Support is here to help. You’ll work with an experienced team member who can:
Help you navigate the insurance process
Work with your health care provider to manage insurance forms
Assist you if there are changes to your insurance coverage
Once you’ve started treatment, your Novartis Patient Support team will be there for you as long as you want them.
Live, one-on-one support is just a phone call away for:
Guidance on your health plan coverage process
Options for saving on your prescription
Setting up your routine and getting more help with KISQALI
Educational resources about KISQALI and living with breast cancer
A welcome kit to help you start on KISQALI
A list of independent support organizations that can offer services to help with treatment
Your choice of texts, calls, and emails to keep you connected to ongoing support
Novartis Patient Support doesn’t replace medical guidance from your health care provider. Our goal is to help you feel informed about your treatment from day one.
There are 3 ways to get started. Once your health care provider prescribes KISQALI, you can:
Have questions?
Call Novartis Patient Support at 866-433-8000, Monday-Friday, 8:00 AM to 8:00 PM ET, excluding holidays.
What is the most important information I should know about KISQALI ?
KISQALI may cause serious side effects, including:
Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or...
KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with: